Trial for Prostate Cancer Vaccine Extends Patient Enrollment to Rutgers Cancer Institute

Trial for Prostate Cancer Vaccine Extends Patient Enrollment to Rutgers Cancer Institute
An ongoing Phase 1 clinical trial evaluating the experimental new vaccine MVI-118 for prostate cancer treatment has been extended to Rutgers Cancer Institute of New Jersey. Patient enrollment is currently open. The trial began last year with patient participation at the University of Wisconsin – Madison. The vaccine was created by Madison Vaccines Incorporated (MVI). Initial data from the

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Tagged , , , , , .

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

Leave a Comment

Your email address will not be published. Required fields are marked *